Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. FEMY
FEMY logo

FEMY Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Femasys Inc (FEMY) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
3.870
1 Day change
-5.15%
52 Week Range
22.200
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Femasys Inc (FEMY) is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock lacks strong bullish confirmation, has no meaningful news catalyst, and the broader technical structure is still bearish. With no strong proprietary buy signal and no supportive financial or analyst momentum provided, the best direct call is to hold and wait rather than buy immediately.

Technical Analysis

Technically, FEMY is mixed to bearish. The MACD histogram is positive and expanding, which shows some short-term momentum improvement. However, RSI_6 at 49.385 is neutral and does not confirm strength. More importantly, the moving averages remain bearish with SMA_200 > SMA_20 > SMA_5, indicating the longer-term trend is still weak. Price is trading near the pivot level of 4.081, with resistance at 4.57 and support at 3.592. This suggests the stock is range-bound and has not yet broken into a convincing uptrend.

Positive Catalysts

  • ["MACD histogram is above zero and expanding, suggesting short-term momentum improvement", "Price is trading close to pivot support, which may offer a modest near-term bounce potential"]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there is no event-driven catalyst", "Moving averages are bearish, showing the broader trend is still weak", "RSI is neutral, so there is no momentum confirmation", "AI Stock Pick shows no signal today", "SwingMax shows no signal recently", "Hedge funds are neutral with no significant activity", "Insiders are neutral with no significant recent buying or selling", "No recent congress trading data available", "No valuation data and financial snapshot is unavailable"]

Financial Performance

No usable latest-quarter financial snapshot was provided because the financial data returned an error. As a result, there is no reliable quarter-over-quarter growth assessment available from the provided data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided, so there is no visible Wall Street consensus shift to support a buy case. Based on the available information, pros are limited to a slight technical momentum improvement, while cons dominate due to weak trend structure, no recent catalyst, and no supportive institutional or insider activity.

Wall Street analysts forecast FEMY stock price to rise
2 Analyst Rating
Wall Street analysts forecast FEMY stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.080
sliders
Low
3
Averages
4.75
High
6.5
Current: 4.080
sliders
Low
3
Averages
4.75
High
6.5
Lake Street
Ben Haynor
Buy
initiated
$1.50
AI Analysis
2026-03-03
Reason
Lake Street
Ben Haynor
Price Target
$1.50
AI Analysis
2026-03-03
initiated
Buy
Reason
Lake Street analyst Ben Haynor initiated coverage of Femasys with a Buy rating and $1.50 price target. FemBloc is the first and only non-surgical alternative that can be performed in an OB/GYN office without incisions, anesthesia, or permanent implants and the device has CE Mark clearance and is currently in a registration trial for PMA approval from the FDA, notes the analyst. The latest data suggests about 1.2M surgical sterilizations occur in the U.S. each year, so this could be "a multi-billion-dollar market for Femasys in the U.S. alone," depending on average selling prices, the analyst tells investors.
Laidlaw
Yale Jen
initiated
$6.50
2025-11-20
Reason
Laidlaw
Yale Jen
Price Target
$6.50
2025-11-20
initiated
Reason
Laidlaw analyst Yale Jen initiated coverage of Femasys with a Buy rating and $6.50 price target. Femasys is a development stage medical technology company focusing on two lead women healthcare products, FemaSeed and FemBloc, the analyst tells investors in a research note. The firm says FemaSeed is exploring a new and large market opportunity via gynecologist channel while FemBloc is heading to pivotal clinical study backed by "robust" prior clinical data.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for FEMY
Unlock Now

People Also Watch